EHA 2022 | Axi-cel plus rituximab for R/R LBCL and updates from the ZUMA-14 study
Paolo Strati, MD, The University of Texas MD Anderson Cancer Center, Houston, TX, shares some insights into the safety and efficacy of axicabtagene ciloleucel (axi-cel) in combination with rituximab for the treatment of relapsed/refractory (R/R) large B-cell lymphoma (LBCL). Dr Strati first discusses the rationale behind the ZUMA-14 trial (NCT04002401) which is investigating this treatment combination, and then highlights some results from this study, including the efficacy of this combination and overall response rates (ORR) observed. To conclude, Dr Strati comments on the benefit of targeting antigens other than CD19 and the promise of dual-targeting CAR-T cells in the future treatment of relapsed disease. This interview took place at the European Hematology Association (EHA) Congress 2022 held in Vienna, Austria.
Disclosures
Advisory Board/Consultancy: Roche Genentech, Hutchinson MediPharma, ADC Therapeutic, TG Therapeutics, Incyte Morphosis, Kite Gilead
Research Support: Astrazeneca Acerta, ADC Therapeutics, Sobi Pharmaceutics, ALX Oncology.
